NextCure pushes LNCB74 -tumor data to H2 2026 as enrollment lags
The B7-H4 antibody-drug conjugate's dose-escalation trial is still recruiting, so the proof-of-concept signal investors want now folds into a later progress update.
Executive Summary
- NextCure shifted the timing of its first look at LNCB74 clinical activity from the first half of 2026 to the second half, attributing the delay to enrollment pace rather than any safety or efficacy finding.
- The underlying Phase 1 study is still recruiting and has just opened higher-dose cohorts aimed at tumor types with high target expression, meaning the delay reflects an earlier trial stage than the original guidance implied.
- The asset sits alone as the only Phase 1 program targeting this receptor in this tumor population, so the eventual update will be the first data point of its kind rather than one benchmarked against a rival readout.
- The H2 2026 update is expected to be a trial progress report, and whether it includes an actual recommended dose or early efficacy signal will determine how much it changes the picture for the program.
The disclosure
NextCure disclosed the timing shift in a January 23, 2026 business update, stating that proof-of-concept data for LNCB74, previously anticipated in the first half of 2026, is delayed to accommodate enrollment. The company said it now expects to provide a trial progress update in the second half of 2026. LNCB74 is an antibody-drug conjugate directed at B7-H4, pairing a tumor-selective cleavable linker with the tubulin inhibitor MMAE, and NextCure shares global co-development rights with LigaChem Biosciences under a cost-sharing arrangement. NextCureNextCure Provides Business UpdateJan 23, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial
The Phase 1 dose-escalation study, NCT06774963, is recruiting in the United States with an anticipated enrollment of 145 patients and a primary completion date of December 1, 2026. Its primary endpoints are defining a recommended Phase 2 dose and evaluating safety and tolerability, with objective response rate, progression-free survival, and disease control rate tracked as secondary measures. The population requires measurable disease by RECIST 1.1, ECOG performance status 0 to 1, and willingness to undergo a tumor biopsy. NCT06774963A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963
Dose expansion
Following a November 2025 protocol amendment, dosing has commenced in higher-dose cohorts that prioritize patients with high B7-H4 expression in breast and gynecological cancers, now including adenoid cystic carcinoma type 1. That expansion narrows the trial toward the tumor types most likely to show a pharmacodynamic or response signal once enrollment completes, which is the population the delayed update will actually characterize. NextCureNextCure Provides Business UpdateJan 23, 2026
The competitive field
LNCB74 is the only Phase 1 asset registered against B7-H4 in this -tumor population, with the closest identified comparator, GlaxoSmithKline's GSK5733584, already in Phase 3 testing for ovarian and endometrial cancer. Across the broader B7-H4 target field, eight active industry trials span five sponsors, with GSK and Hansoh BioMedical the most advanced, and the field has cooled somewhat, with five trials started recently against seven older ones. One prior B7-H4 x tumor trial has completed with no terminations recorded. With no validated disease-modifying mechanism established yet for B7-H4-directed therapy in this setting, a dose-finding result that both defines a tolerable recommended Phase 2 dose and shows objective responses in the newly prioritized high-expression cohorts would be the signal that distinguishes this program from earlier-stage peers.
Sponsor context
NextCure's broader trial portfolio includes three terminated studies against one completed and two currently recruiting, a 25% completion rate across four resolved trials. That track record bears on the company's execution history generally; it does not by itself explain this delay, which the company attributed specifically to enrollment pace in the LNCB74 study. The trial's registry history through the current amendment shows no primary-completion-date changes and no endpoint amendments recorded, consistent with a stable protocol undergoing planned expansion rather than a disrupted one. NextCure+1NextCure Provides Business UpdateJan 23, 2026A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.